ArticleLasers in surgery and medicine2025
Safety Assessment of a 1940 nm Tm:YAP Laser for Fractional Skin Ablation in a Swine Model.
Article in Lasers in surgery and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesThis exploratory study was aimed to evaluate the safety and preliminary efficacy of Epicare, a 1940 nm thulium-doped yttrium aluminum perovskite (Tm:YAP) laser, for fractional skin ablation in a swine model. The goal was to assess collagen remodeling and tissue responses across varied laser settings to optimize skin resurfacing applications. MATERIALS AND
methodsTwo female domestic swine were subjected to controlled fractional laser ablation using Epicare across 52 marked abdominal sites with varying energy settings. Macroscopic examinations of ablated sites were conducted immediately following ablation and at 1, 3, 7, 14, 22, and 29 days postablation. Histopathological evaluation was conducted immediately posttreatment, and at 1, 7, and 29 days postablation. Observed parameters included epidermal regeneration, dermal remodeling, inflammation, and collagen deposition.
resultsMacroscopic evaluations revealed a fractional, clear, and immediate impact of ablation, consisting primarily of erythema and edema, which resolved without complications by Day 14. Histopathological analysis indicated focal, cylinder-like structures associated with necrotic epidermis and dermis, which healed progressively (i.e. from day 1), transitioning to complete epidermal regeneration by Day 7 for most energy settings. By Day 29, advanced collagen deposition and no residual inflammation indicated effective dermal remodeling, consistent with rapid healing and minimal adverse reactions.
conclusionsEpicare demonstrated a favorable safety profile and effective tissue ablation. These findings support the laser's potential for dermatologic applications while emphasizing the need for further investigation to confirm its efficacy and optimal settings in human clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.